妥洛特罗贴剂联合孟鲁司特钠对咳嗽变异性哮喘患儿症状消失时间、肺功能及细胞免疫功能的影响

Effects of Toloterol Patch Combined with Montelukast Sodium on Symptom Disappearance Time,Pulmonary Function and Cellular Immune Function in Children with Cough Variant Asthma

目的探讨妥洛特罗贴剂联合孟鲁司特钠在咳嗽变异性哮喘(CVA)患儿中的应用效果.方法选择2021年8月—2022年5月该院收治的82例CVA患儿,按随机数字表法分为两组,各41例.对照组给予孟鲁司特钠治疗,观察组在对照组基础上加用妥洛特罗贴剂,持续治疗4周.对比两组临床疗效、症状消失时间、肺功能、细胞免疫功能及不良反应发生率.结果观察组治疗总有效率为95.12%(39/41),高于对照组的80.49%(33/41),差异有统计学意义(P<0.05);治疗后,观察组喘憋消失时间(2.84±0.62)d、咳嗽消失时间(6.26±1.24)d、肺部哮鸣音消失时间(5.01±1.06)d、肺部湿啰音消失时间(5.29±1.14)d均短于对照组的(3.47±0.85)d、(7.26±1.68)d、(5.78±1.49)d、(6.57±1.53)d,第1秒用力呼气容积(2.01±0.26)L、1秒率(42.56±9.45)%、呼气流量峰值(6.75±0.98)L/min、CD3^(+)(58.43±5.13)%、CD4^(+)(40.27±4.13)%、CD4^(+)/CD8^(+)(1.63±0.51)均高于对照组的(1.74±0.19)L、(35.21±9.14)%、(5.94±0.81)L/min、(51.15±4.67)%、(36.31±3.87)%、(1.39±0.43),CD8^(+)(20.03±3.05)%低于对照组的(26.21±3.24)%,组间差异有统计学意义(P<0.05);两组不良反应发生率相近,差异无统计学意义(P>0.05).结论妥洛特罗贴剂联合孟鲁司特钠在小儿咳嗽变异性哮喘治疗中的应用效果显著,有利于改善患儿肺功能及细胞免疫功能,加快症状缓解,且安全性高.

Objective To investigate the application effect of toloterol patch combined with montelukast sodium in children with cough variant asthma(CVA).Methods 82 children with CVA admitted to the hospital from August 2021 to May 2022 were selected and divided into two groups according to the random number table method,with 41 cases in each group.The control group was treated with montelukast sodium,and the observation group was treated with toloterol patch on the basis of the control group,with both interventions for 4 weeks.The clinical efficacy,symptom disappearance time,pulmonary function,cellular immune function and incidence of adverse reaction of the two groups were compared.Results The total effective rate of treatment in the observation group was 95.12%(39/41),which was higher than 80.49%(33/41)in the control group,and the differences was statistically significant(P<0.05);after treatment,the asthma disappearance time(2.84±0.62)d,cough disappearance time(6.26±1.24)d,pulmonary wheezing sound disappearance time(5.01±1.06)d and pulmonary moist rale disappearance time(5.29±1.14)d in the observation group were shorter than(3.47±0.85)d,(7.26±1.68)d,(5.78±1.49)d and(6.57±1.53)d in the control group,forced expiratory volume in one second(2.01±0.26)L,one-second rate(42.56±9.45)%,expiratory flow rate(6.75±0.98)L/min,CD3^(+)(58.43±5.13)%,CD4^(+)(40.27±4.13)%,CD4^(+)/CD8^(+)(1.63±0.51)were higher than(1.74±0.19)L,(35.21±9.14)%,(5.94±0.81)L/min,(51.15±4.67)%,(36.31±3.87)%(1.39±0.43)in the control group,CD8^(+)(20.03±3.05)%was lower than(26.21±3.24)%in the control group,the differences between the groups were statistically significant(P<0.05);the incidence of adverse reactions in the two groups was similar,and the difference was not statistically significant(P>0.05).Conclusion The application of toloterol patch combined with montelukast sodium in the treatment of children with CVA has a significant effect,which is conducive to improving the pulmonary function and cellular immune function of children,accelerating symptom relief,and has high safety.